HUP0001434A2 - 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation - Google Patents

5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation

Info

Publication number
HUP0001434A2
HUP0001434A2 HU0001434A HUP0001434A HUP0001434A2 HU P0001434 A2 HUP0001434 A2 HU P0001434A2 HU 0001434 A HU0001434 A HU 0001434A HU P0001434 A HUP0001434 A HU P0001434A HU P0001434 A2 HUP0001434 A2 HU P0001434A2
Authority
HU
Hungary
Prior art keywords
aryl
heterocyclic
6alkyl
heteroaryl
compound
Prior art date
Application number
HU0001434A
Other languages
Hungarian (hu)
Inventor
Shripad S. Bhagwat
Marlon D. Cowart
Anne Laure Grillot
Chih-Hung Lee
Jeffrey Mckie
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HUP0001434A2 publication Critical patent/HUP0001434A2/en
Publication of HUP0001434A3 publication Critical patent/HUP0001434A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgya (I) általános képletű vegyület -, ahol R1 és R2 jelentése egymástól függetlenül hidrogénatom, rövid szénláncúalkil-, (1-6 szénatomos alkoxi)-(1-6 szénatomos alkil)-, aril-(1-6szénatomos alkil)-, -C(O)-1-6 szénatomos alkil-, -C(O)-aril-, -C(O)-heterociklusos csoport, vagy a nitrogénatommal együtt, melyhezkapcsolódnak, 5-7-tagú gyűrűt képeznek, amely adott esetben 1-2további heteroatomot, mégpedig oxigén-, nitrogén- és/vagy kénatomottartalmaz; R3 jelentése rövid szénláncú szénláncú alkil-, rövid szénláncúalkenil-, rövid szénláncú alkinil-, cikloalkil-, aril-, aril-alkil-,heteroaril-, heterociklusos, heteroaril-alkil- vagy heterocikloalkil-csoport, ahol a heteroaril- és heterociklusos csoportok közvetlenülvagy egy gyűrűs szénatomon keresztül közvetve kapcsolódnak; R4 jelentése rövid szénláncú alkil-, rövid szénláncú alkenil-, rövidszénláncú alkinil-, cikloalkil-, aril-, aril-alkil-, heteroaril-,heterociklusos, heteroaril-alkil- vagy heterocikloalkil-csoport; és aszaggatott vonal - - - azt jelenti, hogy adott esetben kettős kötésvan jelen, feltéve, hogy a rendes vegyértékek fennmaradnak -, valamintaz (I) általános képletű vegyület gyógyászatilag hatásos mennyiségétés gyógyászatilag elfogadható hordozót tartalmazó adenozin- kináz-gátló gyógyszerkészítmény. Fenti vegyület így agyi ischémia,epilepszia, fájdalomérzet, gyulladás és szepszis ellenigyógyszerkészítmények előállítására alkalmazható. A találmány kiterjeda vegyületek -, ahol R1, R2, R3 és R4 jelentése a fenti -előállítására is. ÓThe subject of the invention is a compound of general formula (I) -, where R1 and R2 independently represent a hydrogen atom, lower alkyl, (C1-6alkyl)-(C1-6alkyl), aryl-(C1-6alkyl)- , -C(O)-1-6 carbon atom alkyl-, -C(O)-aryl-, -C(O)-heterocyclic group, or together with the nitrogen atom to which they are attached, form a 5-7-membered ring, which contains 1-2 additional heteroatoms, namely oxygen, nitrogen and/or sulfur atoms; R3 is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic, heteroarylalkyl or heterocycloalkyl, where the heteroaryl and heterocyclic groups are directly or are indirectly linked through a ring carbon atom; R4 is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic, heteroarylalkyl or heterocycloalkyl; and a dashed line - - - means that a double bond is present, provided that the normal valences are maintained - and an adenosine kinase inhibitor pharmaceutical preparation containing a medically effective amount of the compound of general formula (I) in a medically acceptable carrier. The above compound can thus be used for the production of medicinal preparations against cerebral ischemia, epilepsy, pain, inflammation and sepsis. The invention also covers the preparation of compounds -, where R1, R2, R3 and R4 have the above meaning. HE

HU0001434A 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation HUP0001434A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16
PCT/US1998/007207 WO1998046605A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors

Publications (2)

Publication Number Publication Date
HUP0001434A2 true HUP0001434A2 (en) 2000-10-28
HUP0001434A3 HUP0001434A3 (en) 2001-01-29

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001434A HUP0001434A3 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation

Country Status (18)

Country Link
EP (1) EP0989986A1 (en)
JP (1) JP2001520655A (en)
KR (1) KR20010006509A (en)
CN (1) CN1252070A (en)
AR (1) AR012436A1 (en)
AU (1) AU7108398A (en)
BG (1) BG103842A (en)
BR (1) BR9809055A (en)
CA (1) CA2286909A1 (en)
CO (1) CO4940446A1 (en)
HU (1) HUP0001434A3 (en)
IL (1) IL131618A0 (en)
NO (1) NO995036D0 (en)
PL (1) PL336304A1 (en)
SK (1) SK141799A3 (en)
TR (1) TR199902455T2 (en)
WO (1) WO1998046605A1 (en)
ZA (1) ZA983177B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
ATE305303T1 (en) 2001-02-12 2005-10-15 Hoffmann La Roche 6-SUBSTITUTED PYRIDOPYRIMIDINES
BR0306982A (en) 2002-01-17 2004-10-26 Neurogen Corp Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to reduce the calcium conductance of a cell capsaicin receptor, to inhibit the binding of vanilloid ligand to a capsaicin receptor in vitro and in a patient, to treat a condition responsive to modulation of the capsaicin receptor in a patient, to treat pain in a patient, to treat itching in a patient, to treat coughing or hiccups in a patient, to promote weight loss in an obese patient, and to determine the presence or absence capsaicin receptor in a sample, packaged pharmaceutical preparation, and use of a compound
DE10335183A1 (en) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungicidal drug combinations
ATE449097T1 (en) * 2005-07-21 2009-12-15 Hoffmann La Roche PYRIDOÄ2,3-DÜPYRIMIDINE-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORS
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
WO2007076034A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab Anti-viral compounds
US8222243B2 (en) * 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
AR068121A1 (en) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd MULTICICLICAL COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES
DE102007061764A1 (en) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
KR20110122746A (en) * 2009-02-26 2011-11-10 에자이 알앤드디 매니지먼트 가부시키가이샤 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN110256420B (en) * 2019-05-07 2020-04-28 江西中医药大学 Tetrahydropyridopyrimidine derivatives, their preparation and use
CN110283171A (en) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 Compound of the one kind containing Pyridopyrimidine -4- amine structure, pharmaceutical composition and its application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
KR20010006509A (en) 2001-01-26
EP0989986A1 (en) 2000-04-05
CN1252070A (en) 2000-05-03
HUP0001434A3 (en) 2001-01-29
TR199902455T2 (en) 2000-01-21
SK141799A3 (en) 2000-08-14
CO4940446A1 (en) 2000-07-24
WO1998046605A1 (en) 1998-10-22
BR9809055A (en) 2000-08-08
IL131618A0 (en) 2001-01-28
NO995036L (en) 1999-10-15
AR012436A1 (en) 2000-10-18
ZA983177B (en) 1999-01-22
NO995036D0 (en) 1999-10-15
PL336304A1 (en) 2000-06-19
AU7108398A (en) 1998-11-11
BG103842A (en) 2000-06-30
JP2001520655A (en) 2001-10-30
CA2286909A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
HUP0001434A2 (en) 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds, pharmaceutical compouads thereof and process for their preparation
HUP0100348A2 (en) Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates
HUP0203122A2 (en) Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401083A2 (en) 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
NZ504336A (en) Tetrahydrofuran substituted adenosine A1 receptor agonists, pharmaceuticals thereof, and their use as medicaments
CA2269994A1 (en) 7-hetero-bicyclo¬2.2.1|-heptanes
HUP0001285A2 (en) Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
NZ511707A (en) Substituted bicyclic derivatives useful as anticancer agents
ATE56721T1 (en) NEW DIPHOSPHONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND MEDICATIONS CONTAINING THESE COMPOUNDS.
HUP0101112A2 (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists and medicaments containing them
HUP0203422A2 (en) Imidazole derivatives as phosphodiesterase vii inhibitors, process for their preparation and pharmaceutical compositions containing them
DE69022294D1 (en) N-Heteroaryl-purin-6-amines, process for their preparation and their use as medicines.
NZ232283A (en) Substituted imidazo(1,2-b)pyridazine derivatives; pharmaceutical compositions and preparatory processes
HUT45983A (en) Process for production of derivatives of imidazolidinone
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
YU64400A (en) Aryl fused azapolycyclic compounds
HUP9701660A2 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, and pharmaceutical compositions containing them
HUP0004588A2 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-oles, method for the production and use thereof as medicaments and pharmaceutical compositions containing them
HUP0101230A2 (en) Chemical process for the production of sulphinyl derivatives by oxidation of the corresponding co-derivatives with perborates
HUP0303593A2 (en) Biguanide derivatives, pharmaceutical compositions containing them and their use
CA2364719A1 (en) 2-aminopyridines containing fused ring substituents
HUP0001443A2 (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds, pharmaceutical compositions thereof and process for preparing them
DE3786865T2 (en) Anticonvulsant compositions containing amino acid derivatives and use of these amino acid derivatives.
HUP0001402A2 (en) 6,7-disubstituted-4-aminopyrido[2,3-d] pyrimidine compounds, pharmaceutical compositions thereof and process for their preparation